SYRS - Syros Qarzning balans kapitallashuviga nisbati

Syros Pharmaceuticals (SYRS) tovar belgisi

Yuqori R&D xarajatlari va FDA ning qat'iy nazorati Syros Pharmaceuticals (SYRS) uchun sezilarli to'siqlarni yaratmoqda. GURU.Markets tomonidan taqdim etilgan ushbu umumiy qarzdorlikning kapitalga nisbati grafigi, qiymat 0.00 darajasida qolganligi sababli, tashqi moliyalashtirishga bog'liqlikni tasdiqlaydi. Joriy savdolarning yo'qligi grantlar bilan qoplanmoqda, saraton terapiyasi uchun kelgusidagi eksklyuzivlik esa kompaniyaga monopol narx belgilash imkoniyatini beradi.

Syros Pharmaceuticals (SYRS) - Balans qiymatiga qarzlar 04.07.2022dan 29.03.2025gacha

Syros Pharmaceuticals Inc. (SYRS) - koʻrsatkichlar kesimi va moliyaviy hisobotlar

- narx va narxlar bo'yicha konsensus prognoz:
Aksiya narxi Syros Pharmaceuticals|SYRS - Tahlilchilar konsensus prognozi
- bozor kapitallashuvi bo'yicha ma'lumotlar:
Bozor qiymati Syros Pharmaceuticals, Inc|SYRS - Kompaniyani sotib olish narxi
- balans kapitallashuvi bo'yicha ma'lumotlar:
Bitta aksiya uchun buxgalteriya qiymati Syros Pharmaceuticals|SYRS - Kompaniyaning xususiy kapitali|Bozor qiymatining balans qiymatiga nisbati syros.com|SYRS - Aktivlarning umumiy qiymati
- qarz va likvidlik bo'yicha ma'lumotlar:
Qarzning xususiy kapitalga nisbati Syros Pharmaceuticals|SYRS - Uzoq muddatli majburiyatlarning kapitalga nisbati|Qisqa muddatli qarzning o'z kapitaliga nisbati Syros|SYRS - Kompaniyaning umumiy qarz majburiyatlari|Qarzning balans qiymatiga nisbati Syros Pharmaceuticals, Inc
Kompaniyaning barcha koʻrsatkichlari tahlili:SYRS, Syros Pharmaceuticals
Syros yetakchi tovari

Syros Pharmaceuticals (SYRS) moliyaviy barqarorligini baholash uning kapital tuzilmasini tahlil qilishni talab qiladi. Ushbu ko'rsatkich qarz mablag'larining o'z kapitaliga nisbatini o'lchab, qarz yuklamasi darajasini belgilaydi. Kitob kapitalizatsiyasiga asoslangan moliyaviy leveraj grafigini o'rganish orqali investor hisobotlardagi kechikishlarsiz to'lov qobiliyati dinamikasini kuzatishi mumkin. Ushbu ko'rsatkichning pasayishi majburiyatlarni qayta tuzilishi muvaffaqiyatli bo'lganini tasdiqlaydi. Endilikda e'tiborC leukemiyalar uchun klinik sinov katalizatorlariga qaratilmoqda.

Syros Pharmaceuticals kimlar bilan raqobatlashadi

Balans kapitallashuviga qarzlar TEM (Tempus AI Inc)|qiagen.com - Balans kapitallashuviga qarzlar|Qarzning balans kapitallashuviga nisbati IONS (Ionis)|Repligen Corp (RGEN) - Sof aktivlarga qarzlar|Qarzning balans qiymatiga nisbati RNA|CRSP (CRISPR) - Balans qiymatiga qarzlar|WGS - Qarzning balans kapitallashuviga nisbati|Qarzning sof aktivlarga nisbati RARE|Beam Therapeutics - Qarzning balans kapitallashuviga nisbati|Balans qiymatiga qarzlar SRPT (Sarepta Therapeutics)|Qarzning balans kapitallashuviga nisbati TWST|TXG - Sof aktivlarga qarzlar|Qarzning balans qiymatiga nisbati Intellia Therapeutics (NTLA)|STOK: Qarzning sof aktivlarga nisbati|Qarzning balans kapitallashuviga nisbati BioLife Solutions (BLFS)|Wave Life Sciences Ltd (WVE) - Qarzlarning balans kapitallashuviga nisbati|MAZE - Balans kapitallashuviga qarzlar|Qarzning sof aktivlarga nisbati Sionna Corp|Balans kapitallashuviga qarzlar PRME|Balans kapitallashuviga qarzlar TSHA (tayshagtx.com)|Qarzning balans kapitallashuviga nisbati uniQure|MeiraGTx Holdings - Qarzning sof aktivlarga nisbati|RGNX: Qarzning balans kapitallashuviga nisbati|SLDB - Qarzning balans qiymatiga nisbati|OCGN: Balans kapitallashuviga qarzlar|pacb.com (PACB) - Balans kapitallashuviga qarzlar|Balans kapitallashuviga qarzlar BNTC|Qarzning balans qiymatiga nisbati Design Therapeutics Inc|Rocket Pharmaceuticals Inc - Balans kapitallashuviga qarzlar|Balans qiymatiga qarzlar 4D Molecular Corp FDMT|Qarzning balans qiymatiga nisbati LXEO (Lexeo Therapeutics, Inc.)|KRRO - Balans kapitallashuviga qarzlar|Qarzning balans qiymatiga nisbati Editas Medicine EDIT|SLN - Qarzning balans kapitaliga nisbati|proqr.com - Balans kapitallashuviga qarzlar|Codexis (CDXS) - Sof aktivlarga qarzlar|Balans kapitallashuviga qarzlar SGMO|Qarzning balans qiymatiga nisbati Nautilus Biotechnology Inc|Balans kapitallashuviga qarzlar MGX|Balans kapitallashuviga qarzlar DTIL (Precision BioSciences Inc.)|Qarzning balans kapitallashuviga nisbati Generation Bio GBIO|Boundless Bio Inc - Qarzning balans kapitallashuviga nisbati|Qarzning balans kapitallashuviga nisbati XCUR (Exicure Corp)|IMNN: Sof aktivlarga qarzlar|phiopharma.com - Qarzning balans kapitallashuviga nisbati|Sof aktivlarga qarzlar Mustang Bio|Qarzning balans qiymatiga nisbati RNAZ (TransCode Therapeutics Inc.)|Balans qiymatiga qarzlar BNGO|Applied DNA Sciences (APDN) - Qarzning balans kapitallashuviga nisbati|Qarzning sof aktivlarga nisbati BLUE (bluebirdbio.com)|Qarzning balans kapitallashuviga nisbati IPA|Sof aktivlarga qarzlar Omega Therapeutics Inc OMGA|Singular Genomics Systems Inc (OMIC) - Balans kapitallashuviga qarzlar|RGLS: Qarzning balans qiymatiga nisbati|Qarzning balans kapitallashuviga nisbati Telesis Bio, Inc.|traconpharma.com (TCON) - Qarzning balans qiymatiga nisbati|UBX (Unity Biotechnology, Inc.) - Balans kapitallashuviga qarzlar